BioLineRx Prices IPO

BioLineRx Ltd., an Jerusalem-based drug company, has priced 28.69 million common shares at $1.74 per share, for an IPO take of approximately $50 million. It will trade on the Tel Aviv Stock Exchange under ticker symbol BLRX, while Clal Finance Underwriting and Leader Capital Markets served as co-lead underwriters. IPO buyers included existing BioLineRx shareholders Teva Pharmaceuticals, Giza Venture Capital, Pitango Venture Capital and Hadasit. The company previously had raised around $32 million in total VC funding. www.biolinerx.com